Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Equivalents (2017 - 2026)

Dr Reddys Laboratories has reported Cash & Equivalents over the past 10 years, most recently at $159.6 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 5.67% year-over-year to $159.6 million; the TTM value through Mar 2026 reached $159.6 million, down 5.67%, while the annual FY2026 figure was $159.6 million, 7.19% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $159.6 million at Dr Reddys Laboratories, down from $169.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $197.5 million in Q1 2022 and troughed at $70.3 million in Q1 2023.
  • A 5-year average of $136.5 million and a median of $159.6 million in 2026 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 64.41% in 2023 and later soared 97.74% in 2025.
  • Year by year, Cash & Equivalents stood at $197.5 million in 2022, then plummeted by 64.41% to $70.3 million in 2023, then increased by 21.73% to $85.6 million in 2024, then soared by 97.74% to $169.2 million in 2025, then decreased by 5.67% to $159.6 million in 2026.
  • Business Quant data shows Cash & Equivalents for RDY at $159.6 million in Q1 2026, $169.2 million in Q1 2025, and $85.6 million in Q1 2024.